Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)

Author(s): Vasilios G. Athyros, Niki Katsiki, Nikolaos Tentolouris

Journal Name: Current Vascular Pharmacology

Volume 14 , Issue 5 , 2016

Become EABM
Become Reviewer

Keywords: Glucagon-like-peptide-1 receptor agonists, dipeptidyl peptidase 4 inhibitors, type 2 diabetes mellitus, cardiovascular disease, heart failure.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [469 - 473]
Pages: 5
DOI: 10.2174/1570161114666160909161537

Article Metrics

PDF: 55